Construction of non-covalent single-chain Fv dimers for hepatocellular carcinoma and their biological functions

World Journal of Hepatology

Volumn 2, Issue 5, 2010, Pages 185-191

  Bie, Cai Qun ^a   Yang, Dong Hua ^b   Liang, Xu Jing ^b   Tang, Shao Hui ^b  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF JINAN UNIVERSITY   (China)

Author keywords

Affinity; Antibody targeted; Diabody; Specificity; Stability

Indexed keywords

EID: 84862592919     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v2.i5.185     Document Type: Article

References (24)

1. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001; 1: 118-129
2. Holliger P, Prospero T, Winter G. "Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 1993; 90: 6444-6448
3. Adams GP, Shaller CC, Dadachova E, Simmons HH, Horak EM, Tesfaye A, Klein-Szanto AJ, Marks JD, Brechbiel MW, Weiner LM. A single treatment of yttrium-90-labeled CHXA- C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res 2004; 64: 6200-6206
4. Takemura S, Asano R, Tsumoto K, Ebara S, Sakurai N, Katayose Y, Kodama H, Yoshida H, Suzuki M, Imai K, Matsuno S, Kudo T, Kumagai I. Construction of a diabody (small recombinant bispecific antibody) using a refolding system. Protein Eng 2000; 13: 583-588
5. Takemura S, Kudo T, Asano R, Suzuki M, Tsumoto K, Sakurai N, Katayose Y, Kodama H, Yoshida H, Ebara S, Saeki H, Imai K, Matsuno S, Kumagai I. A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma. Cancer Immunol Immunother 2002; 51: 33-44
6. Asano R, Kudo T, Nishimura Y, Makabe K, Hayashi H, Suzuki M, Tsumoto K, Kumagai I. Efficient construction of a diabody using a refolding system: anti-carcinoembryonic antigen recombinant antibody fragment. J Biochem 2002; 132: 903-909
7. Casey JL, Napier MP, King DJ, Pedley RB, Chaplin LC, Weir N, Skelton L, Green AJ, Hope-Stone LD, Yarranton GT, Begent RH. Tumour targeting of humanised cross-linked divalent-Fab antibody fragments: a clinical phase I/II study. Br J Cancer 2002; 86: 1401-1410
8. Asano R, Sone Y, Makabe K, Tsumoto K, Hayashi H, Katayose Y, Unno M, Kudo T, Kumagai I. Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent. Clin Cancer Res 2006; 12: 4036-4042
9. Zhou M, Yang DH, Tang SH, Lu XH, Wang W, Li K. Construction, screening and characterization of the single chain variable fragment antibody against human hepatocellular carcinoma. Zhong Guo Bing Li Sheng Li Zha Zhi 2005; 21: 1246-1248
10. Lu XH, Yang DH, Zhou M, Tang SH. [Affinity maturation of a single-chain antibody against hepatocellular carcinoma]. Zhonghua Gan Zang Bing Za Zhi 2006; 14: 19219-19225
11. Ye G, Yang DH, Lu XH, Zhou M, Tang SH, Wang W. Humanization of a single-chain antibody against hepatocellular carcinoma. Zhong Guo Bing Li Sheng Li Zha Zhi 2008; 11: 1144-1150
12. Atwell JL, Breheney KA, Lawrence LJ, McCoy AJ, Kortt AA, Hudson PJ. scFv multimers of the anti-neuraminidase antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies. Protein Eng 1999; 12: 597-604
13. Dolezal O, Pearce LA, Lawrence LJ, McCoy AJ, Hudson PJ, Kortt AA. ScFv multimers of the anti-neuraminidase antibody NC10: shortening of the linker in single-chain Fv fragment assembled in V(L) to V(H) orientation drives the formation of dimers, trimers, tetramers and higher molecular mass multimers. Protein Eng 2000; 13: 565-574
14. Kortt AA, Lah M, Oddie GW, Gruen CL, Burns JE, Pearce LA, Atwell JL, McCoy AJ, Howlett GJ, Metzger DW, Webster RG, Hudson PJ. Single-chain Fv fragments of antineuraminidase antibody NC10 containing five- and tenresidue linkers form dimers and with zero-residue linker a trimer. Protein Eng 1997; 10: 423-433
15. Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM, Marks JD. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer 1998; 77: 1405-1412
16. Le Gall F, Reusch U, Moldenhauer G, Little M, Kipriyanov SM. Immunosuppressive properties of anti-CD3 singlechain Fv and diabody. J Immunol Methods 2004; 285: 111-127
17. Pei XY, Holliger P, Murzin AG, Williams RL. The 2.0-A resolution crystal structure of a trimeric antibody fragment with noncognate VH-VL domain pairs shows a rearrangement of VH CDR3. Proc Natl Acad Sci USA 1997; 94: 9637-9642
18. Perisic O, Webb PA, Holliger P, Winter G, Williams RL. Crystal structure of a diabody, a bivalent antibody fragment. Structure 1994; 2: 1217-1226
19. Wu AM, Chen W, Raubitschek A, Williams LE, Neumaier M, Fischer R, Hu SZ, Odom-Maryon T, Wong JY, Shively JE. Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers. Immunotechnology 1996; 2: 21-36
20. Adams GP, Tai MS, McCartney JE, Marks JD, Stafford WF 3rd, Houston LL, Huston JS, Weiner LM. Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clin Cancer Res 2006; 12: 1599-1605
21. Arndt MA, Krauss J, Rybak SM. Antigen binding and stability properties of non-covalently linked anti-CD22 single-chain Fv dimers. FEBS Lett 2004; 578: 257-261
22. Carmichael JA, Power BE, Garrett TP, Yazaki PJ, Shively JE, Raubischek AA, Wu AM, Hudson PJ. The crystal structure of an anti-CEA scFv diabody assembled from T84.66 scFvs in V(L)-to-V(H) orientation: implications for diabody flexibility. J Mol Biol 2003; 326: 341-351
23. Plückthun A, Pack P. New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology 1997; 3: 83-105
24. Todorovska A, Roovers RC, Dolezal O, Kortt AA, Hoogenboom HR, Hudson PJ. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J Immunol Methods 2001; 248: 47-66